Raymond James Financial Services Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $17.7M | Buy |
38,044
+2,323
| +7% | +$1.12M | 0.02% | 593 |
|
|
2024
Q2 | $16.7M | Buy |
35,721
+5,824
| +19% | +$2.53M | 0.02% | 582 |
|
|
2024
Q1 | $12.5M | Buy |
29,897
+3,999
| +15% | +$1.69M | 0.02% | 704 |
|
|
2023
Q4 | $10.5M | Buy |
25,898
+968
| +4% | +$358K | 0.02% | 730 |
|
|
2023
Q3 | $8.67M | Sell |
24,930
-737
| -3% | -$258K | 0.02% | 760 |
|
|
2023
Q2 | $9.03M | Buy |
25,667
+648
| +3% | +$218K | 0.02% | 749 |
|
|
2023
Q1 | $7.88M | Sell |
25,019
-4,257
| -15% | -$1.28M | 0.01% | 790 |
|
|
2022
Q4 | $8.45M | Buy |
29,276
+6,273
| +27% | +$1.91M | 0.02% | 725 |
|
|
2022
Q3 | $6.66M | Sell |
23,003
-3,290
| -13% | -$947K | 0.01% | 790 |
|
|
2022
Q2 | $7.41M | Sell |
26,293
-283
| -1% | -$75.7K | 0.02% | 746 |
|
|
2022
Q1 | $6.94M | Buy |
26,576
+1,221
| +5% | +$290K | 0.01% | 843 |
|
|
2021
Q4 | $5.57M | Buy |
25,355
+742
| +3% | +$144K | 0.01% | 963 |
|
|
2021
Q3 | $4.46M | Buy |
24,613
+4,047
| +20% | +$790K | 0.01% | 1041 |
|
|
2021
Q2 | $4.15M | Buy |
20,566
+2,619
| +15% | +$548K | 0.01% | 1064 |
|
|
2021
Q1 | $3.86M | Sell |
17,947
-10,040
| -36% | -$2.21M | 0.01% | 1027 |
|
|
2020
Q4 | $6.61M | Buy |
27,987
+7,734
| +38% | +$1.77M | 0.02% | 711 |
|
|
2020
Q3 | $5.51M | Sell |
20,253
-13,614
| -40% | -$3.76M | 0.02% | 715 |
|
|
2020
Q2 | $9.83M | Buy |
+33,867
| New | +$9.18M | 0.03% | 461 |
|
|
2020
Q1 | – | Sell |
-10,807
| Closed | -$2.37M | – | 2861 |
|
|
2019
Q4 | $2.37M | Sell |
10,807
-1,039
| -9% | -$210K | 0.01% | 1088 |
|
|
2019
Q3 | $2.01M | Sell |
11,846
-17,901
| -60% | -$3.17M | 0.01% | 1106 |
|
|
2019
Q2 | $5.46M | Sell |
29,747
-910
| -3% | -$159K | 0.02% | 649 |
|
|
2019
Q1 | $5.64M | Buy |
30,657
+4,688
| +18% | +$866K | 0.02% | 606 |
|
|
2018
Q4 | $4.3M | Sell |
25,969
-8,978
| -26% | -$1.56M | 0.02% | 589 |
|
|
2018
Q3 | $6.74M | Buy |
34,947
+1,567
| +5% | +$279K | 0.03% | 533 |
|
|
2018
Q2 | $5.67M | Buy |
33,380
+986
| +3% | +$153K | 0.03% | 552 |
|
|
2018
Q1 | $5.28M | Buy |
32,394
+13,681
| +73% | +$2.23M | 0.03% | 528 |
|
|
2017
Q4 | $2.8M | Sell |
18,713
-9,643
| -34% | -$1.43M | 0.02% | 764 |
|
|
2017
Q3 | $4.31M | Buy |
28,356
+21,887
| +338% | +$3.29M | 0.03% | 577 |
|
|
2017
Q2 | $834K | Buy |
6,469
+1,397
| +28% | +$168K | 0.01% | 1377 |
|
|
2017
Q1 | $555K | Sell |
5,072
-357
| -7% | -$31.4K | ﹤0.01% | 1504 |
|
|
2016
Q4 | $400K | Sell |
5,429
-3,854
| -42% | -$314K | ﹤0.01% | 1651 |
|
|
2016
Q3 | $810K | Buy |
9,283
+3,751
| +68% | +$354K | 0.01% | 1214 |
|
|
2016
Q2 | $476K | Buy |
5,532
+25
| +0.5% | +$2.16K | ﹤0.01% | 1452 |
|
|
2016
Q1 | $438K | Buy |
+5,507
| New | +$498K | 0.01% | 1331 |
|
Other funds holding VRTX
Raymond James Financial Services Advisors's VRTX Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 6.5% in Q3 2024, buying an estimated $1.12M and bringing the position to 38,044 shares worth $17.7M. The position accounts for 0.02% of the portfolio, ranked #593.
Raymond James Financial Services Advisors first reported a position in VRTX in Q1 2016 and has held it in 34 quarters since. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.
- Raymond James Financial Services Advisors held 38,044 shares of Vertex Pharmaceuticals worth $17.7M as of Q3 2024.
- Raymond James Financial Services Advisors bought 2,323 Vertex Pharmaceuticals shares in Q3 2024, an estimated $1.12M.
- Vertex Pharmaceuticals made up 0.02% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #593 holding.
- Raymond James Financial Services Advisors first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 34 quarters since.
- 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.